精神分裂症和分裂情感障碍患者对 SARS-CoV-2 mRNA 疫苗的抗穗状病毒抗体反应

IF 3.7 Q2 IMMUNOLOGY Brain, behavior, & immunity - health Pub Date : 2024-06-03 DOI:10.1016/j.bbih.2024.100802
Katlyn Nemani , Livia De Picker , Faith Dickerson , Marion Leboyer , Michele Santacatterina , Fumika Ando , Gillian Capichioni , Thomas E. Smith , Jamie Kammer , Kawtar El Abdellati , Manuel Morrens , Violette Coppens , Emily Katsafanas , Andrea Origoni , Sabahat Khan , Kelly Rowe , R.Sarah Ziemann , Ryad Tamouza , Robert H. Yolken , Donald C. Goff
{"title":"精神分裂症和分裂情感障碍患者对 SARS-CoV-2 mRNA 疫苗的抗穗状病毒抗体反应","authors":"Katlyn Nemani ,&nbsp;Livia De Picker ,&nbsp;Faith Dickerson ,&nbsp;Marion Leboyer ,&nbsp;Michele Santacatterina ,&nbsp;Fumika Ando ,&nbsp;Gillian Capichioni ,&nbsp;Thomas E. Smith ,&nbsp;Jamie Kammer ,&nbsp;Kawtar El Abdellati ,&nbsp;Manuel Morrens ,&nbsp;Violette Coppens ,&nbsp;Emily Katsafanas ,&nbsp;Andrea Origoni ,&nbsp;Sabahat Khan ,&nbsp;Kelly Rowe ,&nbsp;R.Sarah Ziemann ,&nbsp;Ryad Tamouza ,&nbsp;Robert H. Yolken ,&nbsp;Donald C. Goff","doi":"10.1016/j.bbih.2024.100802","DOIUrl":null,"url":null,"abstract":"<div><h3>Importance</h3><p>Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.</p></div><div><h3>Objective</h3><p>To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.</p></div><div><h3>Design</h3><p>This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.</p></div><div><h3>Setting</h3><p>A multi-center study including psychiatric healthcare settings in the United States and Europe.</p></div><div><h3>Participants</h3><p>205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.</p></div><div><h3>Main outcomes and measures</h3><p>Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.</p></div><div><h3>Results</h3><p>A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, <em>P</em> = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, <em>P</em> = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, <em>P</em> = 0.96).</p></div><div><h3>Conclusions and Relevance</h3><p>In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.</p></div>","PeriodicalId":72454,"journal":{"name":"Brain, behavior, & immunity - health","volume":"38 ","pages":"Article 100802"},"PeriodicalIF":3.7000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666354624000802/pdfft?md5=be6f3f21a353c1ddec433f95d38a7fea&pid=1-s2.0-S2666354624000802-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder\",\"authors\":\"Katlyn Nemani ,&nbsp;Livia De Picker ,&nbsp;Faith Dickerson ,&nbsp;Marion Leboyer ,&nbsp;Michele Santacatterina ,&nbsp;Fumika Ando ,&nbsp;Gillian Capichioni ,&nbsp;Thomas E. Smith ,&nbsp;Jamie Kammer ,&nbsp;Kawtar El Abdellati ,&nbsp;Manuel Morrens ,&nbsp;Violette Coppens ,&nbsp;Emily Katsafanas ,&nbsp;Andrea Origoni ,&nbsp;Sabahat Khan ,&nbsp;Kelly Rowe ,&nbsp;R.Sarah Ziemann ,&nbsp;Ryad Tamouza ,&nbsp;Robert H. Yolken ,&nbsp;Donald C. Goff\",\"doi\":\"10.1016/j.bbih.2024.100802\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Importance</h3><p>Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.</p></div><div><h3>Objective</h3><p>To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.</p></div><div><h3>Design</h3><p>This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.</p></div><div><h3>Setting</h3><p>A multi-center study including psychiatric healthcare settings in the United States and Europe.</p></div><div><h3>Participants</h3><p>205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.</p></div><div><h3>Main outcomes and measures</h3><p>Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.</p></div><div><h3>Results</h3><p>A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, <em>P</em> = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, <em>P</em> = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, <em>P</em> = 0.96).</p></div><div><h3>Conclusions and Relevance</h3><p>In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.</p></div>\",\"PeriodicalId\":72454,\"journal\":{\"name\":\"Brain, behavior, & immunity - health\",\"volume\":\"38 \",\"pages\":\"Article 100802\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666354624000802/pdfft?md5=be6f3f21a353c1ddec433f95d38a7fea&pid=1-s2.0-S2666354624000802-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain, behavior, & immunity - health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666354624000802\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, behavior, & immunity - health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666354624000802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

重要性精神分裂症患者在接种疫苗后发生严重 COVID-19 疾病和严重突破性感染的风险较高。目的评估精神分裂症或分裂情感性障碍(SZ)患者接种疫苗后的抗SARS-CoV-2尖峰抗体滴度与无精神障碍的对照组相比是否存在差异。设计这项队列研究评估了接种第一剂和第二剂 mRNA 疫苗后抗体反应的纵向时间点,最长时间为接种第一剂疫苗后 7 周。参与者205名无COVID-19感染史的成年人,包括106名SZ患者和99名无精神障碍的对照者,他们在2020年12月20日至2021年5月27日期间接种了第一剂SARS-CoV-2 mRNA疫苗。结果共纳入 205 人(平均 [SD] 年龄 44.7 [12.0] 岁;男性 90 [43.9%]),其中 106 人(51.7%)被诊断为 SZ。在对年龄、性别、体重指数、吸烟、接种天数和疫苗生产商进行调整后,SZ 与较低的平均对数抗体水平相关(-0.15;95% CI,-0.27 至 -0.03,P = 0.016)。在剂量特异性反应的二次分析中,SZ 与第二剂疫苗后较低的平均对数抗体水平相关(-0.23;95% CI -0.39 至 -0.06,P = 0.006),但与第一剂疫苗无关(0.00;95% CI -0.18- 0.结论和相关性在这项针对 SZ 患者和无精神障碍对照组的队列研究中,SZ 与接种 2 剂 SARS-CoV-2 mRNA 疫苗后较低的 SARS-CoV-2 抗尖峰抗体水平有关。这强调了进一步研究评估精神分裂症患者疫苗免疫原性的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder

Importance

Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.

Objective

To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.

Design

This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.

Setting

A multi-center study including psychiatric healthcare settings in the United States and Europe.

Participants

205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.

Main outcomes and measures

Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.

Results

A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, P = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, P = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, P = 0.96).

Conclusions and Relevance

In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Brain, behavior, & immunity - health
Brain, behavior, & immunity - health Biological Psychiatry, Behavioral Neuroscience
CiteScore
8.50
自引率
0.00%
发文量
0
审稿时长
97 days
期刊最新文献
Attachment State of Mind and complex traumatization in patients with Functional Motor Disorder (Motor Conversion Disorder) Immune cells and the trajectories of depression, anxiety, and cognitive function among people with amyotrophic lateral sclerosis Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia Genetic association of the kynurenine pathway to suicidal behavior EBNA-1 and VCA-p18 immunoglobulin markers link Epstein-Barr virus immune response and brain’s myelin content to fatigue in a community-dwelling cohort
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1